Clinical trials
Atopic Dermatitis (Eczema) clinical trials
Below are recruiting atopic dermatitis (eczema) clinical trials, each written for real people, not researchers. We’re tracking 70 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07239947RecruitingPhase 1
Testing BBT001 for healthy volunteers and people with eczema
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
Hefei, AnhuiAges 18–65 - NCT05674695Recruiting
Registry study for starting or switching atopic eczema medicines
This study follows people with atopic eczema when they start or switch to a specific medicine that affects the immune system. It helps doctors understand how these treatments work in real life, including for skin symptoms and daily quality of life.
Badalona, BarcelonaAges Any age - NCT07645820Recruiting
Testing a device to detect eczema flares early
This study tests a non-invasive home device called Nevisense Go that may help detect atopic dermatitis (eczema) flares before they become severe. You'll use the device at home, track your symptoms, and visit the clinic a few times to see if it helps predict when flares are coming.
Phoenix, ArizonaAges 12–89 - NCT05492578Enrolling by invitationPhase 2/Phase 3
Long-term follow-up of amlitelimab for moderate to severe eczema
This trial studies the long-term safety and effectiveness of amlitelimab in people with moderate to severe atopic dermatitis (eczema). You may be eligible if you previously joined an amlitelimab eczema study and are continuing into a longer follow-up phase.
Birmingham, AlabamaAges 12 years+ - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT07558668RecruitingPhase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Arkansas City, ArkansasAges 18–65 - NCT06239311RecruitingPhase 3
Methotrexate vs placebo for adults with eczema
This trial tests if methotrexate, a medication that calms the immune system, can help adults with moderate-to-severe eczema that hasn't improved with creams or other treatments. You'll either receive methotrexate or a placebo to see which works better.
Prague, Praha 1Ages 18 years+ - NCT06807281RecruitingPhase 3
Abrocitinib for children with eczema: long-term study
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
Birmingham, AlabamaAges 2–11 - NCT05316805Recruiting
Study for type 2 inflammatory skin rashes and hives
This study looks at people with certain types of inflammatory skin conditions to improve how they are diagnosed and treated. It may help your care team by using a standardized approach, but you must be able to complete questionnaires and consent to participate.
BeijingAges Any age - NCT05938478Recruiting
Pregnancy registry for outcomes after tralokinumab exposure
This study tracks pregnancy and baby outcomes in people who have been pregnant while taking tralokinumab, a medication for eczema. It compares those outcomes to other eczema treatment groups to help doctors understand potential risks or reassuring effects.
La Jolla, CaliforniaAges Any age - NCT07347743Recruiting
Probiotic supplement for crying and colic in healthy newborns
This trial tests whether a daily probiotic supplement can reduce excessive crying and colic in healthy, full-term newborns. If your baby is healthy and born at UZ Brussel, this study may help find a gentle way to soothe colic.
Jette, Brussels CapitalAges 1 day–2 weeks - NCT00605878Recruiting
Skin microbiome study in healthy people and eczema patients
This study looks at the types of germs on the skin (skin microbiome) in healthy people and people with skin conditions, including atopic dermatitis (eczema). Researchers collect skin samples to understand how skin germs differ and how that may relate to skin health.
Bethesda, MarylandAges 2–100 - NCT07660835RecruitingPhase 2
A study of nemolizumab for babies with eczema
This trial tests a medicine called nemolizumab for babies aged 6 to 23 months with moderate to severe eczema. The goal is to see if it reduces itching and improves skin symptoms.
San Antonio, TexasAges 6 months–1.9 years - NCT07453602RecruitingPhase 1
Study of ARQ-234 for healthy adults and those with atopic dermatitis
This trial tests a new medication called ARQ-234 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study looks at how the body handles single and multiple doses, and if it can help treat eczema.
Fair Lawn, New JerseyAges 18–65 - NCT06136767Recruiting
Registry for systemic eczema treatments
This study is a registry for people with eczema (atopic dermatitis) who are under 26 and have taken or plan to take body-wide treatments like pills or injections. By joining, you help researchers track how these treatments work over time.
Baltimore, MarylandAges 1–26 - NCT06389136RecruitingPhase 3
Study of upadacitinib for eczema after dupilumab didn't work
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Birmingham, AlabamaAges 18–63 - NCT05994976Recruiting
Collecting skin samples from people with skin conditions
This study collects skin samples (like small biopsies or swabs) from people with certain skin conditions and from healthy volunteers. The samples help researchers learn more about these conditions and may lead to better treatments.
Montreal, QuebecAges 18 years+ - NCT06564389RecruitingPhase 1
First-in-human study of PF-07832837 in healthy adults and eczema patients
This trial is testing a new investigational medicine (PF-07832837) for safety in healthy adults and in people with moderate to severe atopic dermatitis (eczema). It is a first-in-human study, so it looks at how well the body tolerates the medicine.
Anaheim, CaliforniaAges 18–70 - NCT05858619RecruitingPhase 4
Study of skin response to dupilumab in eczema
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
San Francisco, CaliforniaAges 18 years+ - NCT06765005RecruitingPhase 1/Phase 2
Study of MG-K10 for Teens with Moderate to Severe Eczema
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
Hangzhou, ZhejiangAges 12–18 - NCT07455578RecruitingPhase 1
Study of S-4321 for people with autoimmune or immune diseases
This trial tests a new medicine, S-4321, for people with various autoimmune conditions like rheumatoid arthritis, psoriasis, eczema, or lupus. It aims to see if the drug is safe and can help control the overactive immune system.
Charlestown, New South WalesAges 18–75 - NCT06744569Enrolling by invitationPhase 1
Testing a new ointment for atopic dermatitis in healthy adults and patients
This trial tests a new ointment called CU-10101. It will first be tested in healthy volunteers to check safety, and then in people with atopic dermatitis (eczema) to see how well it works for mild to moderate symptoms.
Shanghai, Shanghai MunicipalityAges 18–65
Hear when a new Atopic Dermatitis (Eczema) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atopic dermatitis (eczema)?
- Yes. Clin2 currently lists 70 recruiting atopic dermatitis (eczema) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atopic dermatitis (eczema) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atopic dermatitis (eczema) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.